Erratum to: Rheumatol Int DOI 10.1007/s00296-014-3047-6

Unfortunately, the probability values in the section “Chemokine and cytokine results” was incorrect in the published article.

The correct section should read as follows:

There was a significant decrease between the initial and final serum levels in interleukin-1α (IL), IL-1β, IL-6, IL-8, IL-10, IL-12, IL-17α, interferon (IFN), tumor necrosis factor alpha (TNF-α), and granulocyte macrophage colony-stimulating factor (GM-CSF) in the oral GAGs group (P < 0.05). The placebo group had significant increases in IL-1α, IL-1β, IL-2, IL-4, IL-6, and TNF-α (P < 0.05). There was also a significant decrease between the initial and final SF levels in most chemokines and cytokines in the oral GAGs group (P < 0.05), whereas the placebo group had significant increases in IL-10, IFN, TNF-α, and GM-CSF (P < 0.05). Overall, the oral preparation had decreased serum and synovial cytokine levels while patients on placebo had increased levels over the same 12 weeks.